Home / Why SelfPap™

Why SelfPap™

SelfPap™ impacts the Cervical Cancer, HPV, STI and STD Crisis

The Cervical Cancer Crisis

STAT: Worldwide, cervical cancer is the fourth most frequent cancer in women with an estimated 530,000 new cases in 2012 representing 7.5% of all female cancer deaths.

Cervical cancer kills an estimated 275,000 women every year. This entirely preventable disease is the second largest cancer killer of women in low and middle‐income countries, with most women dying in the prime of life.

For the facts we used current data derived from official reports by the WHO (World Health Organization), United Nations, The World Bank, and IARC Globocan that highlight the inequity that women face depending on where they live. Fifty countries were selected to provide a snapshot of the world and reflect geographic, economic and population variations. The Cervical Cancer Crisis Card reveals that India ranks No. 1 in cervical cancer deaths with nearly 73,000 women dying of cervical cancer each year. China comes in second, followed by Brazil.

* STAT: 50% of women diagnosed with cervical cancer have NEVER had a pap test

* STAT: 10% of women diagnosed with cervical cancer have not had a pap test in 5 YEARS

Many more women die of cervical cancer in the developing world than in wealthier countries. In the industrialized world, effective screening programs help to identify precancerous cervical lesions at a stage when they can easily be treated. But lack of screening programs in poorer countries means that the disease is not identified until it is too late, resulting in vastly greater mortality. Source: WHO/Globocan.

Cervical Cancer Chart

The STD Crisis

STDs are hidden epidemics of enormous health and economic consequence in the United States. They are hidden because many Americans are reluctant to address sexual health issues in an open way and because of the biologic and social characteristics of these diseases.”

~ Division of STD Prevention November 2015 Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Globally the data is staggering and often under reported. Based upon a meta-analysis published by the World Health Organization (October 14, 2014), the adjusted HPV prevalence worldwide among women with normal cytological findings was estimated to be 11.7%.

CDC Sees ‘Alarming’ Increase in Sexually Transmitted Diseases

CDC Fact Sheet 2014 National Data for Chlamydia, Gonorrhea, and Syphilis

This fact sheet summarizes 2014 data on chlamydia, gonorrhea, and syphilis published in CDC’s annual report, Sexually Transmitted Disease Surveillance, 2014  (available at www.cdc.gov/std/stats). The data are based on state and local STD case reports from a variety of private and public sources. They indicate that the majority of cases are reported in non-STD clinic settings, such as private physician offices and health maintenance organizations.

Many cases of chlamydia, gonorrhea, and syphilis continue to go undiagnosed and unreported, and data on several additional STDs — such as human papillomavirus, herpes simplex virus, and trichomoniasis — are not routinely reported to CDC. As a result, the annual surveillance report captures only a fraction of the true burden of STDs in America. However, it provides important insights into the scope, distribution, and trends in STD diagnoses in the country.

STDs are a substantial health challenge facing the United States. CDC estimates that nearly 20 million new sexually transmitted infections occur every year in this country, half among young people aged 15–24, and account for almost $16 billion in health care costs. Each of these infections is a potential threat to an individual’s immediate and long-term health and well-being. In addition to increasing a person’s risk for acquiring and transmitting HIV infection, STDs can lead to severe reproductive health complications, such as infertility and ectopic pregnancy.